Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

Rhea-AI Summary

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) will host a webcast on October 6, 2022, at 8:00 a.m. ET to report top-line results from Part 1 of the Phase 3 GUARD Trial for ADX-2191, an innovative treatment for proliferative vitreoretinopathy (PVR), a vision-threatening condition without available therapies. The conference call can be accessed via a dial-in number or through a live audio webcast on the company’s website, with archived access for 90 days post-event.

Positive

• Initiating a Phase 3 GUARD Trial for ADX-2191, indicating progress in clinical development.
• Potential to address a significant medical need in treating proliferative vitreoretinopathy.

Negative

• None.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, October 6, 2022, at 8:00 a.m. (ET) to report top-line results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 (methotrexate injection, United States Pharmacopeia) for intravitreal administration in patients with proliferative vitreoretinopathy (PVR), a rare, sight-threatening ocular disease with no approved therapy.

The dial-in numbers are (844) 200-6205 for domestic callers and (646) 904-5544 for international callers. The access code is 005042. A live audio webcast of the conference call also will be accessible from the “Investors & Media” section of Aldeyra's website at ir.aldeyra.com.

After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.

About Aldeyra

Aldeyra is a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in late-stage clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (methotrexate injection, United States Pharmacopeia) for intravitreal administration, in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005669/en/

Investor & Media:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: (857) 383-2409

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.

FAQ

What is the purpose of the GUARD Trial for ADX-2191?

The GUARD Trial aims to evaluate the efficacy of ADX-2191, a methotrexate injection for treating proliferative vitreoretinopathy.

When will Aldeyra report results from the GUARD Trial?

Aldeyra will report top-line results from Part 1 of the GUARD Trial on October 6, 2022.

What is the significance of the Phase 3 GUARD Trial results for ALDX shareholders?

The results could impact Aldeyra's market position and define the future of ADX-2191, potentially influencing stock performance.

How can investors access the Aldeyra conference call?

Investors can dial in using provided numbers or stream the live webcast from Aldeyra's website.